Assessing efficacy in myelofibrosis treatment: A focus on JAK inhibition

Expert Review of Hematology

Volumn 5, Issue 6, 2012, Pages 631-641

  Komrokji, Rami ^a   Verstovsek, Srdan ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CYT387; JAK; JAK STAT; Janus kinase; LY2784544; Myelofibrosis; Pacritinib; Quality of life; Ruxolitinib; SAR302503

Indexed keywords

ANTIANEMIC AGENT; CORTICOSTEROID; GANDOTINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; LENALIDOMIDE; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE TYK2; RECOMBINANT ERYTHROPOIETIN; RUXOLITINIB; STAT3 PROTEIN; THALIDOMIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANDROGEN THERAPY; ANEMIA; BONE PAIN; CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; ECCHYMOSIS; ENZYME INHIBITION; ERYTHROCYTE TRANSFUSION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HEPATOMEGALY; HUMAN; LOW DRUG DOSE; MORBIDITY; MYALGIA; MYELOFIBROSIS; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SATIETY; SIGNAL TRANSDUCTION; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; ULCER; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84870946696     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.50     Document Type: Review

References (63)

1. Barosi G, Mesa RA, Thiele J et al.; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2), 437-438 (2008).
2. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 25(2), 218-225 (2011).
3. Tefferi A. Myelofibrosis with myeloid metaplasia. N. Engl. J. Med. 342(17), 1255-1265 (2000).
4. Passamonti F, Cervantes F, Vannucchi AM et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9), 1703-1708 (2010).
5. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105(3), 973-977 (2005).
6. Mesa RA, Niblack J, Wadleigh M et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109(1), 68-76 (2007).
7. Mesa RA, Schwager S, Radia D et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk. Res. 33(9), 1199-1203 (2009).
8. Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13), 2895-2901 (2009).
9. Cervantes F, Pereira A, Esteve J et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br. J. Haematol. 97(3), 635-640 (1997).
10. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int. J. Hematol. 73(2), 194-198 (2001).
11. Gangat N, Caramazza D, Vaidya R et al. DIPSS-Plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 29(4), 392-397 (2011).
12. Barbui T, Barosi G, Birgegard G et al.; European Leukemia Net. Philadelphianegative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J. Clin. Oncol. 29(6), 761-770 (2011).
13. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am. J. Hematol. 83(6), 491-497 (2008).
14. Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin. Cancer Res. 16(7), 1988-1996 (2010).
15. Verstovsek S, Mesa RA, Gotlib J et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366(9), 799-807 (2012).
16. Harrison C, Kiladjian JJ, Al-Ali HK et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366(9), 787-798 (2012).
17. Pardanani A, Gotlib JR, Jamieson C et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol. 29(7), 789-796 (2011).
18. Pardanani A, George G, Lasho T et al. A Phase I/II study of CYT387, an oral JAK- 1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. ASH Annual Meeting Abstracts 116(21), 460 (2010).
19. Komrokji R, Wadleigh M, Seymour JF et al. Results of a Phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts 118(21), 282 (2011).
20. Verstovsek S, Mesa RA, Rhoades SK et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). ASH Annual Meeting Abstracts 118(21), 2814 (2011).
21. Tefferi A, Barosi G, Mesa RA et al.; IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108(5), 1497-1503 (2006).
22. Verstovsek S, Kantarjian HM, Estrov Z et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6), 1202-1209 (2012).
23. Verstovsek S, Kantarjian H, Mesa RA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363(12), 1117-1127 (2010).
24. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 112(2), 231-239 (2008).
25. Ballen KK, Shrestha S, Sobocinski KA et al. Outcome of transplantation for myelofibrosis. Biol. Blood Marrow Transplant. 16(3), 358-367 (2010).
26. Mesa RA, Kantarjian H, Tefferi A et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 117(21), 4869-4877 (2011).
27. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 362(9384), 640-650 (2003).
28. Cella D, Yount S, Rothrock N et al.; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med. Care 45 (5 Suppl 1), S3-S11 (2007).
29. Cella D, Webster K, Cashy J et al. Development of a measure of health-related quality of life for non-Hodgkin's lymphoma clinical research: the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym). ASH Annual Meeting Abstracts 106(11), 750 (2005).
30. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85(5), 365-376 (1993).
31. Huang J, Li C, Mesa R et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112(12), 2727-2732 (2008).
32. Tefferi A, Siragusa S, Hussein K et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis - prognostic relevance is independent of IPSS or karyotype. Am. J. Hematol. 85(1), 14-17 (2010).
33. Gale R, Barosi G, Barbui T et al. What are RBC transfusion dependence and independence? Leuk. Res. 35(1), 8-11 (2011).
34. Martínez-Trillos A, Gaya A, Maffioli M et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann. Hematol. 89(12), 1233-1237 (2010).
35. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu. Rev. Med. 60, 233-245 (2009).
36. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95(7), 2226-2233 (2000).
37. Cervantes F. Modern management of myelofibrosis. Br. J. Haematol. 128(5), 583-592 (2005).
38. Reilly JT, McMullin MF, Beer PA et al.; Writing group: British Committee for Standards in Haematology. Guideline for the diagnosis and management of myelofibrosis. Br. J. Haematol. 158(4), 453-471 (2012).
39. Alchalby H, Kröger N. Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis. Curr. Hematol. Malig. Rep. 5(2), 53-61 (2010).
40. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of janus kinases. Immunol. Rev. 223, 132-142 (2008).
41. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat. Rev. Drug Discov. 10(2), 127-140 (2011).
42. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas- Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer 117(4), 662-676 (2011).
43. Lee CK, Raz R, Gimeno R et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17(1), 63-72 (2002).
44. Ghaffari S, Kitidis C, Zhao W et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 107(5), 1888-1891 (2006).
45. Sakamoto H, Kitamura T, Yoshimura A. Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells. J. Biol. Chem. 275(46), 35857-35862 (2000).
46. Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93(3), 385-395 (1998).
47. Neubauer H, Cumano A, Muller M, et al. Jak2 defiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409 (1998)
48. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak-Stat- Socs pathway in disease. Mol. Immunol. 44(10), 2497-2506 (2007).
49. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered janus-activated kinase-STAT3 binding. Cancer Res. 69(5), 1958-1965 (2009).
50. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118(7), 1723-1735 (2011).
51. Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3(7), e270 (2006).
52. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352(17), 1779-1790 (2005).
53. Baxter EJ, Scott LM, Campbell PJ et al.; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464), 1054-1061 (2005).
54. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4), 387-397 (2005).
55. Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356(5), 459-468 (2007).
56. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 112(6), 2190-2198 (2008).
57. Quintás-Cardama A, Vaddi K, Liu P et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15), 3109-3117 (2010).
58. Verstovsek S. Myeloproliferative disorders: JAK2 and beyond. In: The American Society of Clinical Oncology 2012 Educational Book. The American Society of Clinical Oncology, VA, USA, 256-261 (2011).
59. Pardanani A, Gotlib J, Gupta V et al. An expanded multicenter Phase I/II study of CYT387, a JAK- 1/2 inhibitor for the treatment of myelofibrosis. ASH Annual Meeting Abstracts 118(21), 3849 (2011).
60. Talpaz M, Hamburg SI, Jamieson K et al. Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50-100 x 109/L. J. Clin. Oncol. 30, Abstract 6630 (2012).
61. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 120(7), 1367-1379 (2012).
62. US FDA website: ruxolitinib. www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/ CDER/ucm280155.htm?utm-source =fdaSearch&utm- medium=website&utm- term=ruxolitinib&utm-content=1 (Accessed 4 April 2012)
63. US National Institutes of Health. ClinicalTrials.gov website. www.clinicaltrials.gov (Accessed 28 June 2012)